


Company


EditForce Inc.

Presenter


**Yuki
Tanabe**



Next-generation Gene Editing / RNA manipulation Technology

“PPR Protein” Our Core technology



- PPR is based on proteins
- Recognize DNA/RNA sequences
- We can design Target Specific PPR

 DNA binding
PPR protein
 

 RNA binding
PPR protein
 

Therapeutic Indication

Gene Editing

- Cell Therapy, "ex-vivo" uses
- CAR-T, Immuno-Oncology

RNA Targeted Therapy

- Neurological Disorder
- Splicing Abnormalities
- Eye Disease

Potential Collaboration

1. Co-development of “Gene Editing Platform Technology”
2. Joint-research & development of “RNA Targeted Therapies”
3. Capital investment to EditForce Inc.